BIO-TOP study n=125 | DRESS study n=102 | |
Demographics | ||
Age (years)* | 57 (12) | 59 (10) |
Female gender | 81 (65) | 62 (61) |
Disease duration (years)† | 4 (1–10) | 11 (6–17) |
RF positive | 74/123 (60) | 80 (78) |
ACPA positive | 65/116 (56) | 73 (72) |
Disease characteristics | ||
DAS28-CRP* | 4.0 (1.1) | 2.2 (0.6) |
TJC† | 4 (2–9) | 0 (0–1) |
SJC† | 4 (1–7) | 0 (0–0) |
PGA, VAS 0–100 mm*‡ | 62 (20) | 23 (17) |
CRP (mg/L)† | 5 (1–19) | 3 (3) |
ESR (mm/hour)†‡ | 17 (7-31) | 12 (7–20) |
Calprotectin (ng/mL)† | 680 (433–1252) | 612 (475-927) |
Treatment characteristics | ||
Number of previous bDMARDs† | 0 (0–1) | 0 (0–1) |
Current TNFi | ||
ADA | 50 (40) | 38 (37) |
ETN | 75 (60) | 64 (63) |
Duration current TNFi (years)† | NA | 3 (2–6) |
Concomitant treatment | ||
csDMARDs | 97 (78) | 59 (58) |
MTX | 66 (53) | 46 (45) |
NSAIDs | 80 (64) | 57 (56) |
Oral glucocorticoids | 22 (18) | 5 (5) |
Data presented as number (%) unless otherwise noted.
*Mean (SD).
†Median (p25–p75).
‡Missing data BIO-TOP study; in eight patients (6%) PGA is missing and in nine patients (7%) ESR is missing. If PGA was missing, DAS28-CRP was calculated with three variables: TJC, SJC and CRP.
ACPA, anti-citrullinated protein antibodies; ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; BIO-TOP, Biologic Individual Optimised Treatment Outcome Prediction; CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; DAS28-CRP, 28-joint count Disease Activity Score using CRP; DRESS, Dose Reduction Strategies of Subcutaneous TNF Inhibitors; ESR, erythrocyte sedimentation rate; ETN, etanercept; MTX, methotrexate; NA, not applicable; NSAID, non-steroidal anti-inflammatory drug; PGA, patient global assessment of disease activity; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale.